Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Drugs In Development, 2022, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.
Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 21 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Genital Herpes - Overview
Genital Herpes - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Genital Herpes - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Genital Herpes - Companies Involved in Therapeutics Development
Genital Herpes - Drug Profiles
Genital Herpes - Dormant Projects
Genital Herpes - Discontinued Products
Genital Herpes - Product Development Milestones
Featured News & Press Releases
Oct 18, 2021: United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University partner on world's first long-acting Herpes Treatment UB-621
Jul 22, 2021: Rational Vaccines receives UK MHRA Innovation Passport for RVx201 for the treatment of genital herpes resulting from herpes simplex type 2 (HSV-2) virus
Nov 10, 2020: United BioPharma received IND approval from China NMPA for UB-621 Phase 2 trial in patients with Recurrent Genital Herpes
Sep 20, 2019: New Penn-Developed Vaccine Prevents Herpes in Mice, Guinea Pigs
Jun 10, 2019: United BioPharma receives US FDA approval for UB-621 Phase 2 trial in recurrent Genital Herpes Patients
Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study
Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
Feb 03, 2016: Model helps decide drug dose for clinical testing
Nov 15, 2015: IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA)
Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine
Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Genital Herpes, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Genital Herpes - Pipeline by Abivax SA, 2022
Genital Herpes - Pipeline by AiCuris Anti-infective Cures AG, 2022
Genital Herpes - Pipeline by AlphaVax Inc, 2022
Genital Herpes - Pipeline by Anteris Technologies Ltd, 2022
Genital Herpes - Pipeline by Astellas Pharma Inc, 2022
Genital Herpes - Pipeline by Auritec Pharmaceuticals Inc, 2022
Genital Herpes - Pipeline by Auro Vaccines LLC, 2022
Genital Herpes - Pipeline by Biomere LLC, 2022
Genital Herpes - Pipeline by BioNTech SE, 2022
Genital Herpes - Pipeline by BlueWillow Biologics Inc, 2022
Genital Herpes - Pipeline by Brandenburg Antiinfektiva GmbH, 2022
Genital Herpes - Pipeline by GlaxoSmithKline Plc, 2022
Genital Herpes - Pipeline by iosBio Pharma Ltd, 2022
Genital Herpes - Pipeline by NanoViricides Inc, 2022
Genital Herpes - Pipeline by Nykode Therapeutics AS, 2022
Genital Herpes - Pipeline by Rational Vaccines Inc, 2022
Genital Herpes - Pipeline by Sanofi, 2022
Genital Herpes - Pipeline by Shulov Innovative Science Ltd, 2022
Genital Herpes - Pipeline by SL VaxiGen Inc, 2022
Genital Herpes - Pipeline by Starpharma Holdings Ltd, 2022
Genital Herpes - Pipeline by United BioPharma Inc, 2022
Genital Herpes - Pipeline by Vaxart Inc, 2022
Genital Herpes - Pipeline by Vir Biotechnology Inc, 2022
Genital Herpes - Pipeline by Vironova Medical AB, 2022
Genital Herpes - Pipeline by Wuhan Binhui Biotechnology Co Ltd, 2022
Genital Herpes - Dormant Projects, 2022
Genital Herpes - Dormant Projects, 2022 (Contd..1)
Genital Herpes - Dormant Projects, 2022 (Contd..2)
Genital Herpes - Discontinued Products, 2022
List of Figures
Number of Products under Development for Genital Herpes, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
